Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to a novel, uncharacterized transcript on the strand opposite the DZANK1 gene (double zinc ribbon and ankyrin repeat domains 1), labeled as "antisense to DZANK1." Antisense transcripts are RNA molecules that are complementary to sense transcripts, and can sometimes regulate gene expression through various mechanisms such as RNA interference or modulation of transcription, but there is no published functional evidence or known protein product for this transcript. There are no reports of direct biological function, disease association, or drug relevance for this transcript. The entry may be incomplete, misspecified, or simply unannotated, and does not correspond to a typical therapeutic target class such as receptor, enzyme, or transporter.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to DZANK1 (ENSG00000304667).